Insight Molecular Diagnostics
IMDX
23 hedge funds and large institutions have $21.1M invested in Insight Molecular Diagnostics in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 5 closing their positions.
65% more capital invested
Capital invested by funds: $12.8M → $21.1M (+$8.27M)
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
0.52% more ownership
Funds ownership: 52.9% → 53.42% (+0.52%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 25 → 23 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadwood Capital
New York
|
+$6.65M |
| 2 |
AIC
AWM Investment Company
New York
|
+$942K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$83.2K |
| 4 |
FIA
FNY Investment Advisers
New York
|
+$65K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$47.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$122K |
| 2 |
PVI
Pura Vida Investments
New York
|
-$78.6K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$9.3K |
| 4 |
Renaissance Technologies
New York
|
-$4.95K |
| 5 |
DC
Defender Capital
Charlotte,
North Carolina
|
-$1.83K |
IMDX Hedge Fund Activity: Q2 2024 in Review
23 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q2 2024, worth a combined $21.1M — up 65% from $12.8M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of IMDX and 3 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 8 added.
The largest buyer was Broadwood Capital, adding an estimated $6.65M. The largest seller was Morgan Stanley, cutting an estimated $122K.
- 23 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q2 2024, down from 25 in Q1 2024.
- Funds reported $21.1M of Insight Molecular Diagnostics stock for Q2 2024, up 65% quarter-over-quarter.
- 3 funds opened new Insight Molecular Diagnostics positions in Q2 2024 and 5 closed out, a net change of -2 holders.
- The largest Insight Molecular Diagnostics buyer in Q2 2024 was Broadwood Capital, an estimated $6.65M added.
- The largest Insight Molecular Diagnostics seller in Q2 2024 was Morgan Stanley, an estimated $122K sold.
Based on aggregated 13F filings for Q2 2024.